泛复舒联合体位引流治疗支气管扩张的临床研究

摘要

目的 探讨泛福舒联合体位引流对支气管扩张患者治疗的临床疗效.方法 选择支气管扩张患者78例,经过急性期治疗病情得到控制后,以自愿原则随机双盲分为两组,对照组单纯体位引流,治疗组口服泛福舒的同时体位引流,观察两组患者3个月后免疫指标变化和6个月内临床症状即每日咳嗽咳痰量及呼吸道再次感染次数.结果 治疗组病例咳嗽咳痰的症状减轻显著高于对照组(P=0.046),呼吸道再次感染次数显著下降(P=3.43× 10-12);治疗组治疗后CD4+、CD4+/CD8+、NK细胞活性值均较治疗前明显提高(P＜0.0 1),CD8+活性值较治疗前降低(P＜ 0.01).对照组治疗前后CD4+、CD4+/CD8+、NK值均无明显变化.治疗组患者体内IgG、IgA的表达水平在治疗后显著高于对照组患者(P＜0.01).结论 泛福舒联合体位引流可减少支气管扩张患者每日咳嗽及咳痰量,降低呼吸道再次感染发病率,增强机体免疫力.且泛福舒药物耐受性好,副反应小.%Objective To investigate the clinical effect of Broncho-Vaxom combined with postural drainage in the treatment of bronchiectasis.Methods 78 cases of bronchiectasis whose acute phase condition was under control after treatment,were randomly double-blind divided into two groups.Control group received postural drainage,and treatment group received Broncho-Vaxom capsule combined with postural drainage.Compared immune indexes after 3 months and clinical symptoms including cough and expectoration,number of respiratory infection during 6 months between two groups.Results Cough and expectoration symptoms after treatment in treatment group were better than those in control group (P=0.046),the number of respiratory tract infection was lower (P=3.43× 1012).Expression levels of CD4+,CD4+/CD8+,NK after treatment improved significantly in treatment group (P＜0.01),expression level of CD8+ decreased (P＜0.01).Expression levels of CD4+,CD4+/CD8+,NK in control group before and after treatment did not change significantly.The levels of IgG and IgA after treatment in treatment group were significantly higher those in control group (P＜0.01).Conclusions Broncho-Vaxom combined with postural drainage can relieve cough and expectoration symptoms of bronchiectasis patients,reduce the incidence of respiratory tract infection,enhance body immunity.Broncho-Vaxom has a good drug tolerance,with slight side effect.